Pharmafile Logo

5 takeaways from Reuters’ Pharma USA 2026 – and what they mean for you

April 15, 2026 |  

Pharma USA is North America’s largest cross-functional pharma event and Inizio was there to offer insights on patient engagement, accelerated product launches, and Intelligent Commercialization™. Now we’re back in the office, it’s time to share our thoughts on some of the key themes discussed in Philadelphia.

- PMLiVE

More than a dozen colleagues from Inizio IgniteInizio Engage, and Inizio Evoke attended Pharma USA 2026 in mid-March. While we were there, we ran a workshop on designing insight-driven patient support, and hosted a live session on the practical strategies pharma teams can employ to drive focus, alignment, and smarter product launch execution.

These types of events are an excellent way to take the pulse of pharma and, with more than 170 speakers and 20 interactive sessions, Pharma USA was once again a hive of interesting ideas and hot topics.

1. AI is everywhere – but the real differentiator is the quality of the data behind it.

It’s no surprise that conversations about AI were happening everywhere at Pharma USA, but one of the more interesting takes wasn’t about the amazing things the technology can do, but how quality data is fundamental to its successful implementation.

What became clear in conversations across the event is that while many organizations are investing heavily in AI, those seeing real impact are the ones grounding it in well-structured, proprietary data and embedding it into real decision-making workflows.

In a landscape where teams are already navigating increasing complexity, more stakeholders, and compressed timelines, simply adding more data or tools does not guarantee better outcomes. The real question is whether those inputs are improving decision quality and enabling action at speed.

Read the full article here. 

This content was provided by Inizio

Company Details

 Latest Content from  Inizio 

Article: Pricing a coronavirus vaccine

Using findings from Research Partnership's recent COVID-19 impact study, Market Access Directors Rachel Howard and Brett Gardiner and Consultant Suzan Serip explore the challenges of pricing a coronavirus vaccine. Read...

News: Living with Ulcerative Colitis and Crohn’s Disease

Living with Ulcerative Colitis (UC) and Crohn’s Disease (CD) are new patient syndicated reports which offer valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs. These reports...

Interactive infographic

Living With: The journey from the patient’s perspective

Article: Spotlight on Mexico

Healthcare under AMLO – One year on

News: Mandira Kar joins London Headquarters as Qualitative Research Director

Research Partnership are delighted to announce that Mandira Kar has joined as a Qualitative Research Director. Mandira is an expert in ethnography with over 15 years’ experience in market research,...

Announcing a change of leadership at the US Philadelphia office

Research Partnership’s Philadelphia office is announcing a change of leadership from the start of 2020. President Harriet Kozak will be stepping down in order to take retirement at the end...

Article: Market access in Brazil

All eyes on Spinraza

China: How to strategise and win in the world’s fastest changing healthcare market

In this paper, experts Marc Yates, Pei Li Teh and Brett Gardiner discuss the China healthcare reforms which affect pharma and propose how to build the market understanding required to launch...

Article: Engaging patient advocacy groups

The key to conducting effective rare disease research